Published in Cancer Weekly, July 18th, 2006
"The obvious benefit of PLD for tumor control in recurrent ovarian cancer is frequently offset by severe PPE. There is evidence that dose reduction from 50 to 40 mg/m2 reduces the incidence of PPE without compromising cytotoxic activity. We set out to investigate whether biweekly application further improves the therapeutic index of PLD," scientists in Germany report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.